NAPO PHARMACEUTICALS INC
Pharmaceutical therapeutics across multiple clinical indications
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Latest Form D
- $138K, Jun 2014
- Total capital
- $10.4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $10.1M
- 5 Form D · last Jun 2014
- 149 months since last filing
- Federal contracts
- $335K
- 9 awards · Veterans Affairs
- Rank in Biotech#255 of 4373
- Granted patents
- 7
- 26 pending · first 2015
- Rank in peer group#213 of 1449
Capital timeline
Latest events
- Federal contractVeterans Affairs · Pharm - Mytesi$76K
- Federal contractVeterans Affairs · Mytesi$42K
- Federal contractVeterans Affairs · Mytesi Oral Tabs$3K
- Federal contractVeterans Affairs · Mytesi$42K
- Federal contractVeterans Affairs · Mytesi 125MG Tablet$41K
- Federal contractVeterans Affairs · Pharmacy Drugs$33K
- Federal contractVeterans Affairs · Mytesi (crofelemer) 125MG Tabs, Ec$32K
- Private capital raisedForm D · SEC · 5th filing$138K
- Private capital raisedForm D · SEC · 4th filing$3.1M
- Private capital raisedForm D · SEC · 3rd filing$3M
- Private capital raisedForm D · SEC · 2nd filing$3.4M
- Private capital raisedForm D · SEC · 1st filing$500K
Show 2 earlier federal awards
- Federal contractVeterans Affairs · Crofelemer 125MG Tablet, Ec 70564-0802-60$32K
- Federal contractVeterans Affairs · Crofelemer 125MG Tablet$32K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Lisa ConteResearcherExecutive OfficerLinked by 3 patents
- Charles ThompsonExecutive OfficerNamed in SEC Form D filings
- Dennis FentonDirectorNamed in SEC Form D filings
- Gregory StockDirectorNamed in SEC Form D filings
- Jack Van HulstDirectorNamed in SEC Form D filings
- Joshua MailmanDirectorNamed in SEC Form D filings
Show all 12 people
- Pravi ChaturvediExecutive OfficerNamed in SEC Form D filings
- Pravin ChaturvediExecutive OfficerNamed in SEC Form D filings
- Richard FieldsDirectorNamed in SEC Form D filings
- Sir William YoungDirectorNamed in SEC Form D filings
- Steven KingExecutive OfficerNamed in SEC Form D filings
- Thomas Van DyckDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 33- PendingLyophilized Formulation Of Crofelemer And Methods Of Treatment Using The SameUSPTOApplication 19116891
- PendingAlstonine Derivatives And Salts ThereofUSPTOApplication 18704315
- PendingMethods And Compositions For Treating Congenital Diarrhea DisorderUSPTOApplication 18520464
Show all 33 patent records
- Lyophilized Formulation Of Crofelemer And Methods Of Treatment Using The SameApr 16, 2026 · Application 19116891Pending
- Alstonine Derivatives And Salts ThereofDec 26, 2024 · Application 18704315Pending
- Methods And Compositions For Treating Congenital Diarrhea DisorderOct 3, 2024 · Application 18520464Pending
- Alstonine Derivatives and Salts ThereofJun 27, 2024 · Application 18562605Pending
- Methods And Compositions For Treating Congenital Diarrhea DisorderJan 2, 2024 · US 11,857,510Granted
- Methods And Compositions For Treating Bile Acid Diarrhea, Diarrhea Associated With Small Intestine Resection Or Gallbladder Removal, And Short Bowel SyndromeOct 10, 2023 · US 11,779,564Granted
- Methods And Compositions For Treating Chemotherapy-induced DiarrheaNov 17, 2022 · Application 17866453Pending
- Methods And Compositions For Treating Chemotherapy-induced DiarrheaJul 19, 2022 · US 11,389,424Granted
- Compositions And Methods For Treating Or Preventing Inflammatory Bowel Disease, Familial Adenomatous Polyposis And Colon CancerJun 5, 2018 · US 9,987,250Granted
- Method For Treatment Of Diarrhea-predominant Irritable Bowel SyndromeMay 29, 2018 · US 9,980,938Granted
- Methods And Compositions For Treating Hiv-associated DiarrheaMar 7, 2017 · US 9,585,868Granted
- Pharmacologically Optimized Multimodal Drug Delivery System For Nordihydroguiaretic Acid (ndga)Dec 1, 2015 · US 9,198,879Granted
- Compositions And Methods Of Treatment With Proanthocyanidin Polymer Antidiarrheal CompositionsNov 6, 2014 · Application 14276231Pending
- Methods And Compositions For Treating Hiv-associated DiarrheaOct 2, 2014 · Application 14307175Pending
- Methods And Compositions For Treating Hiv-associated DiarrheaJun 12, 2014 · Application 13840861Pending
- Pharmacologically Optimized Multimodal Drug Delivery System For Nordihydroguiaretic Acid (ndga)Application PCTUS2012034675Pending
- Methods Of Treating Diseases With Proanthocyanidin Oligomers Such As CrofelemerApplication PCTUS2010051530Pending
- Compositions And Methods For Treating Or Preventing Inflammatory Bowel Disease, Familial Adenomatous Polyposis And Colon CancerApplication PCTUS2007067741Pending
- Method For Treatment Of Constipation-predominant Irritable Bowel SyndromeApplication PCTUS2007067739Pending
- Lyophilized Formulation Of Crofelemer And Methods Of Treatment Using The SameApplication PCTUS2023034050Pending
- Alstonine Derivatives And Salts ThereofApplication PCTUS2022047892Pending
- Lyophilized Formulation Of CrofelemerApplication 63410988Pending
- Alstonine Derivatives And Salts ThereofApplication PCTUS2022033451Pending
- Methods And Compositions For Treating Post-acute Infection Gastrointestinal DisordersApplication PCTUS2021060624Pending
- Alstonine Derivatives and Salts ThereofApplication 63272146Pending
- Alstonine Derivatives and Salts ThereofApplication 63210255Pending
- Use of Crofelemer for Treatment of Post-acute Infection Gastrointestinal SyndromeApplication 63117933Pending
- Methods And Compositions For Treating Chemotherapy-induced DiarrheaApplication PCTUS2020038691Pending
- Methods And Compositions For Treating Bile Acid Diarrhea, Diarrhea Associated With Small Intestine Resection Or Gallbladder Removal, And Short Bowel SyndromeApplication PCTUS2018035471Pending
- Methods And Compositions For Treating Congenital Diarrhea DisorderApplication PCTUS2018035468Pending
- Methods And Compositions For Treating Short Bowel SyndromeApplication 62513257Pending
- Methods And Compositions For Treating Congenital Diarrhea DisorderApplication 62513251Pending
- Methods And Compositions For Treating Chemotherapy-induced DiarrheaApplication 62469133Pending
Related companies, and why
- AFASCI, INC.Similar federal contract value in Biotech · $339K in contracts
- Telesis Bio Inc.Similar federal contract value in Biotech · $337K in contracts
- QUALITY BIOLOGICAL, INC.Similar federal contract value in Biotech · $336K in contracts
- Ovation.io, Inc.Similar federal contract value in Biotech · $329K in contracts
- Beta Hatch Inc.Similar federal contract value in Biotech · $324K in contracts
- Celltheon CorpSimilar federal contract value in Biotech · $322K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .